Abciximab Suppresses the Rise in Levels of Circulating Inflammatory Markers After Percutaneous Coronary Revascularization - Lincoff, A.Michael; Kereiakes, Dean J.; Mascelli, Mary A.; Deckelbaum, Lawrence I.; Barnathan, Elliot S.; Patel, Kamlesh K.; Frederick, Bart; Nakada, Marian T.; Topol, Eric J. (Circulation (New York, N.Y.), 2001)
Keywords: Abciximab; Angioplasty, Balloon, Coronary - adverse effects; Antibodies, Monoclonal - administration & dosage; Biological and medical sciences; Biomarkers - blood; C-Reactive Protein - metabolism; Diseases of the cardiovascular system; Female; Humans; Immunoglobulin Fab Fragments - administration & dosage; Inflammation - blood; Inflammation - etiology; Inflammation - prevention & control; Infusions, Intravenous; Interleukin-6 - blood; Male; Medical sciences; Middle Aged; Platelet Aggregation Inhibitors - administration & dosage; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects); Treatment Outcome; Tumor Necrosis Factor-alpha - metabolism; United States; Human; Abciximab; Treatment efficiency; Antiinflammatory agent; Cytokine; Coronary artery; Instrumentation therapy; Biological marker; Cuffed tube; Exploration; Instrumental dilatation; Interleukin 6; Chemotherapy; Treatment; C reactive protein; Tumor necrosis factor α